Zyvox

Linezolid

Gm +ve bacteria; vancomycin-resistant Enterococcus faecium infections including cases w/ concurrent bacteremia; nosocomial pneumonia caused by Staph aureus (methicillin-susceptible & -resistant strains) or Strep pneumoniae (including multi-drug resistant strains [MDRSP]); complicated skin & skin structure infections including diabetic foot infections w/o concomitant osteomyelitis caused by Staph aureus (methicillin-susceptible & -resistant strains), Strep pyogenes or Strep agalactiae; uncomplicated skin & skin structure infections caused by Staph aureus (methicillin-susceptible only) or Strep pyogenes; community-acquired pneumonia caused by Strep pneumoniae (including MDRSP) including cases w/ concurrent bacteremia or Staph aureus (methicillin-susceptible strains only).

Adult & adolescent ≥12 yr Complicated skin & skin structure infections, nosocomial & community-acquired pneumonia including concurrent bacteremia 600 mg IV or PO every 12 hr for 10-14 days. Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia 600 mg IV or PO every 12 hr for 14-28 days. Uncomplicated skin & skin structure infections 400 mg PO every 12 hr for 10-14 days in adults & 600 mg PO every 12 hr for 10-14 days in adolescents ≥12 yr. Infection due to MRSA 600 mg every 12 hr in adult. Ped patients (birth through 11 yr) Complicated skin & skin structure infections, nosocomial & community-acquired pneumonia including concurrent bacteremia 10 mg/kg IV or PO every 8 hr for 10-14 days. Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia 10 mg/kg IV or PO every 8 hr for 14-28 days. Uncomplicated skin & skin structure infections 10 mg/kg PO every 12 hr for 10-14 days in childn 5-11 yr & 10 mg/kg PO every 8 hr for 10-14 days in childn <5 yr. Pre-term neonate <7 days (gestational age <34 wk) Initially 10 mg/kg every 12 hr. May be given 10 mg/kg every 8 hr by 7 days of life.

May be taken with or without food.

Hypersensitivity. Patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis; carcinoid syndrome. Concomitant use w/ MAOIs A or B (eg, phenelzine, isocarboxazid); directly & indirectly acting sympathomimetics (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine); serotonin re-uptake inhibitors, TCAs, serotonin 5-HT₁ receptor agonists (triptans), meperidine, buspirone.

Discontinue use if signs or symptoms of rhabdomyolysis are observed. Consider discontinuation of therapy in patients who develop or have worsening myelosuppression. Not for use against gm -ve pathogens; in patients w/ catheter-related bloodstream infections; viral infections eg, common cold. Clostridium difficile-associated diarrhea; pseudomembranous colitis in patients w/ diarrhea; lactic acidosis; hyponatremia & SIADH; peripheral & optic neuropathy in patients treated >28 days; convulsions. Superinfection. History or risk factors for seizures; HTN. Long-term use (>28 days). Patients who develop recurrent nausea or vomiting, unexplained acidosis or low bicarbonate level while on treatment; w/ uncontrolled HTN, pheochromocytoma, carcinoid syndrome or untreated hyperthyroidism; at high risk for life-threatening systemic infections (eg, those w/ infections related to central venous catheters in ICU). Phenylketonuria. Monitor CBC wkly especially in patients treated for >2 wk w/ pre-existing myelosuppression, severe renal insufficiency or moderate to severe hepatic impairment & receiving concomitant drugs that produce bone marrow suppression, or w/ chronic infection who have received previous or concomitant antibiotic therapy. Consider fluid & electrolyte management, protein supplementation & treatment w/ antibacterial against Clostridium difficile in moderate to severe case of pseudomembranous colitis. Closely observe patients for signs & symptoms of serotonin syndrome eg, cognitive dysfunction, hyperpyrexia, hyperreflexia & incoordination. Regularly monitor serum Na levels in elderly, patients taking diuretics & at risk of hyponatremia. Prompt ophth evaluation if visual impairment symptoms appear eg, changes in visual acuity & color vision, blurred vision or visual field defect. Monitor visual function in all patients treated for extended periods (≥3 mth) & patients reporting new visual symptoms regardless of length of therapy. Avoid large quantities of food or beverages w/ high tyramine content; quantities of tyramine consumed should be <100 mg per meal. Concomitant use w/ serotonergic agents, including antidepressants eg, SSRIs & opioids; rifampin; pseudoephedrine HCl- or phenylpropanolamine HCl-containing cold remedies & decongestants; serotonin re-uptake inhibitors or other antidepressants. Thrombocytopenia in patients w/ severe renal insufficiency, whether or not on dialysis, & in patients w/ moderate to severe hepatic impairment. Pregnancy & lactation.

Moniliasis; pancytopenia, leucopenia, thrombocytopenia, anemia, sideroblastic anemia; anaphylaxis; lactic acidosis; convulsions, peripheral neuropathy, headache, taste alteration; optic neuropathy; vomiting, diarrhea, nausea, abdominal pain, cramps & distension, tongue & superficial tooth discoloration; bullous skin disorders including severe cutaneous adverse reactions (eg, TEN & SJS), angioedema, hypersensitivity vasculitis, rash; rhabdomyolysis; abnormal hematology tests & LFTs.

Reversible enhancement of pressor response to indirect-acting sympathomimetics, vasopressor or dopaminergics. Serotonin syndrome w/ serotonergic agents including antidepressants eg, SSRIs.

Other Antibiotics

J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.

FC tab: D; Infusion: S